Business
ViaDerma, Inc. will Seek BFAD (Bureau of Food and Drugs) Approval for its topical antibiotic in the Philippines as Preliminary Studies for the FDA Registered Product Show Promising Results
ViaDerma, Inc. will Seek BFAD (Bureau of Food and Drugs) Approval for its topical antibiotic in the Philippines as Preliminary Studies for the FDA Registered Product Show Promising Results.
About this update from Viaderma, Inc.
[{"type":"text","content":"\nViaDerma, Inc. will Seek BFAD (Bureau of Food and Drugs) Approval for its topical antibiotic in the Philippines as Preliminary Studies for the FDA Registered Product Show Promising Results\n\nViaDerma, Inc. will Seek BFAD (Bureau of Food and Drugs) Approval for its topical antibiotic in the Philippines as Preliminary Studies for the FDA Registered Product Show Promising Results\n\n\nViaDerma and its Partners in the Philippines Look to Expand Initial Test Studies to Major Hospitals in a Move to get its FDA Registered Topical Antibiotic Approved by BFAD for various conditions as it Eyes Huge Market for its Products \n\n LOS ANGELES, CA--(Marketwired - July 10, 2017) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that the Company seeks to expand its initial testing to major Hospitals in the Philippines in a move to gain approval by the BFAD, the Philippines equivalent to the Unites States Food and Drug Administration. The initial testing has already shown promising results and the next move is to expand the \"Clinical Trials\" of its topical antibiotic to well respected hospital groups in the Philippines. The product's positive and quick results have created excitement by doctors and distributors throughout the country. The Distributors are also interested in ViaDerma's several follow-on products, using ViaDerma's proprietary solution, which the Company is expecting additional FDA registration numbers throughout the rest of 2017. The Company's President, Dr. Christopher Otiko said, \"The quick response by patients in our initial testing has shown positive results and this has led to an increased interest in our products due to the need in this part of the world. The next logical move is to seek BFAD approval and open the door for future products in this huge market. The closer we are to distribution it seems we are pleasantly surprised by Distributors' inquiries for our product. Our contract manufacturer has the capabilities to manufacture most of our products and we look forward to building a lasting relationship to deliver high quality pharmaceuticals to our distributors.\"Shareholder Update & Current Share Structure:ViaDerma, Inc., has total Authorized 400,000,000 shares, the issued and outstanding is 380,214,603 shares of Common St...